Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...

Confounded by a confusing expression or dream from a patient, I might seemingly shift gears and ask myself, 'What if this ...

ProBio, a global contract development and manufacturing organization (CDMO), announced that it will present six poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th ...

In addition, a trial-in-progress poster on SUPRAME ... IMA203 is an autologous, engineered T-cell receptor T-cell therapy (TCR T) that targets PRAME, an intracellular protein displayed as a ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

2508 Poster Presentation Title: SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR T) vs investigator's choice in patients with previously ...

HUD was supposed to bring social justice to American cities. Instead, it's left a "trail of failed developments in every ...

Therapeutics announced the presentation of a poster containing data on a new DRP, Drug Response Predictor, for the monoclonal ...